Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 53% year on year to $476.1 million. The company’s full-year revenue guidance of $1.91 billion at the midpoint came in 5.8% above analysts’ estimates. Its GAAP loss of $0.41 per share was 9.3% below analysts’ consensus estimates.
(Bloomberg) -- For two years, Wall Street traders have minted profits simply by chasing the hottest stocks in the market regardless of price, fundamentals or the economic backdrop. Those days appear to be over.Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC’s Congestion Pricing Pulls In $48.6 Million in First MonthNew York’s Con
Voice AI recognition company SoundHound (NASDAQ:SOUN) announced better-than-expected revenue in Q4 CY2024, with sales up 101% year on year to $34.54 million. Its GAAP loss of $0.69 per share was significantly below analysts’ consensus estimates.
Apple device management company, Jamf (NASDAQ:JAMF) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 8.2% year on year to $163 million. On the other hand, next quarter’s revenue guidance of $166.5 million was less impressive, coming in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.17 per share was 11% above analysts’ consensus estimates.
Programmatic advertising platform Pubmatic (NASDAQ: PUBM) missed Wall Street’s revenue expectations in Q4 CY2024 as sales only rose 1.1% year on year to $85.5 million. Next quarter’s revenue guidance of $62 million underwhelmed, coming in 5.9% below analysts’ estimates. Its non-GAAP profit of $0.41 per share was 9.6% above analysts’ consensus estimates.
Residential solar energy company Sunrun (NASDAQ:RUN) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $518.5 million. Its non-GAAP profit of $1.41 per share was significantly above analysts’ consensus estimates.
The S&P 500 fell 1.6% on Thursday, Feb. 27, as Nvidia led semiconductor and AI stocks lower and investors digested President Trump's latest announcement on tariffs.
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next quarter’s revenue guidance of $57.7 million underwhelmed, coming in 1.6% below analysts’ estimates. Its GAAP profit of $0.49 per share was in line with analysts’ consensus estimates.
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.
Senior living provider The Pennant Group (NASDAQ:PNTG) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 29.4% year on year to $188.9 million. The company’s full-year revenue guidance of $832.5 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $0.24 per share was in line with analysts’ consensus estimates.
